UCB (UCBJF) Stock Price, News & Analysis

Company Overview

UCB S.A. is a global biopharmaceutical company headquartered in Brussels, Belgium, specializing in the research, development and commercialization of treatments for severe diseases in immunology and neurology. The company’s portfolio includes therapies for conditions such as rheumatoid arthritis, Crohn’s disease and various forms of epilepsy. UCB’s flagship products include CIMZIA® (certolizumab pegol) for autoimmune disorders, KEPPRA® (levetiracetam) and VIMPAT® (lacosamide) for seizure management, among others under development targeting central and peripheral nervous system disorders.

Founded in 1928 as Union Chimique Belge, UCB initially focused on chemicals and pharmaceuticals before evolving into a dedicated biopharma enterprise. Over the decades, the company has expanded through research partnerships, strategic acquisitions and in-house innovation, building a pipeline of investigational drugs aimed at unmet medical needs. Its R&D operations span Belgium, the United States and Asia, with key research facilities located in Braine-l’Alleud (Belgium) and Raleigh (North Carolina, U.S.).

UCB markets its products across more than 40 countries, with commercial and manufacturing facilities in Europe, North America and Asia-Pacific. The company employs a multi-regional approach to supply chain management and patient support programs, working closely with health authorities, physicians and patient organizations to facilitate access to its therapies. UCB also invests in digital health initiatives and biomarker research to enhance personalized treatment and patient outcomes.

As of the latest available information, UCB is led by President and Chief Executive Officer Jean-Christophe Tellier, under whose guidance the company continues to pursue sustainable growth and scientific innovation. Governance is overseen by a Board of Directors representing diverse expertise in biopharma, finance and global healthcare. UCB remains committed to advancing its pipeline and strengthening its global footprint in pursuit of improving the lives of patients with chronic and severe diseases.

Key Stats

• Today's Range: $239.04 to $239.04
• 50-Day Range: $193.85 to $240.49
• 52-Week Range: $150.70 to $240.49
• Volume: 95 shs
• Average Volume: 1,394 shs
• Market Capitalization: $45.18 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

UCBJF Stock Analysis - Frequently Asked Questions

How have UCBJF shares performed this year?

UCB's stock was trading at $197.0250 at the start of the year. Since then, UCBJF stock has increased by 21.3% and is now trading at $239.04.

How do I buy shares of UCB?

Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:UCBJF
• CIK: 1290640
• Web: www.ucb.com
• Phone: (322) 559-9999
• Fax: 32-2559-9900
• Employees: 9,083
• Year Founded: 1928

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 1.19
• Quick Ratio: 0.78

Sales & Book Value

• Annual Sales: $5.27 billion
• Price / Sales: 8.58
• Cash Flow: $10.27 per share
• Price / Cash Flow: 23.28
• Book Value: $50.52 per share
• Price / Book: 4.73

Miscellaneous

• Outstanding Shares: 189,020,000
• Free Float: N/A
• Market Cap: $45.18 billion
• Optionable: Not Optionable
• Beta: 0.47